Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Executive Director, Head of Contracts will manage a growing legal contracts team that currently consists of five attorneys, and four contracts managers and chair the Company’s cross-functional Contracts Management Committee. This role will have responsibility for leading the development of the company’s global contracting process and strategy in coordination with regional leadership teams. The Executive Director, Head of Contracts is a leadership role and will be instrumental in the success of the company’s legal team in its support of RevMed’s growth and evolution.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive
Education Level
Ph.D. or professional degree
Number of Employees
251-500 employees